Innovent Biologics (OTCMKTS:IVBXF) vs. Dyne Therapeutics (NASDAQ:DYN) Critical Analysis

Innovent Biologics (OTCMKTS:IVBXF) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider and Institutional Ownership

96.7% of Dyne Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Innovent Biologics and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovent Biologics	N/A	N/A	N/A
Dyne Therapeutics	N/A	-64.30%	-50.33%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Innovent Biologics and Dyne Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovent Biologics	0	0	0	0	0.00
Dyne Therapeutics	1	2	10	2	2.87

Dyne Therapeutics has a consensus target price of $34.42, suggesting a potential upside of 32.47%. Given Dyne Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Innovent Biologics.

Valuation and Earnings

This table compares Innovent Biologics and Dyne Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovent Biologics	N/A	N/A	N/A	N/A	N/A
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.33)	-7.80

Summary

Dyne Therapeutics beats Innovent Biologics on 6 of the 8 factors compared between the two stocks.

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.